Brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to post sales of $4.01 million for the current quarter, Zacks reports. Five analysts have made estimates for Five Prime Therapeutics’ earnings, with the highest sales estimate coming in at $8.34 million and the lowest estimate coming in at $2.00 million. Five Prime Therapeutics reported sales of $4.03 million in the same quarter last year, which indicates a negative year-over-year growth rate of 0.5%. The business is expected to announce its next quarterly earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year sales of $15.04 million for the current financial year, with estimates ranging from $11.70 million to $20.00 million. For the next year, analysts anticipate that the firm will post sales of $33.08 million, with estimates ranging from $20.00 million to $62.30 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08). The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $4.33 million. Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%.
NASDAQ FPRX traded up $0.28 during trading on Friday, reaching $4.37. 382,931 shares of the company traded hands, compared to its average volume of 381,204. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.93 and a current ratio of 6.93. The stock’s 50 day moving average price is $3.83 and its two-hundred day moving average price is $5.20. The company has a market cap of $148.84 million, a price-to-earnings ratio of -1.06 and a beta of 2.39. Five Prime Therapeutics has a 1-year low of $3.18 and a 1-year high of $13.84.
In related news, major shareholder Bvf Partners L. P/Il acquired 16,000 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was purchased at an average price of $3.74 per share, for a total transaction of $59,840.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bvf Partners L. P/Il acquired 1,120,010 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was bought at an average price of $3.40 per share, with a total value of $3,808,034.00. The disclosure for this purchase can be found here. Insiders bought a total of 3,498,133 shares of company stock worth $14,201,410 over the last three months. 7.10% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of FPRX. Man Group plc raised its position in Five Prime Therapeutics by 95.9% in the 2nd quarter. Man Group plc now owns 1,160,411 shares of the biotechnology company’s stock worth $6,997,000 after purchasing an additional 568,017 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Five Prime Therapeutics by 86.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock valued at $6,930,000 after acquiring an additional 533,100 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter valued at $3,128,000. Marshall Wace LLP bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter valued at $2,094,000. Finally, Morgan Stanley raised its position in shares of Five Prime Therapeutics by 1,167.3% during the 2nd quarter. Morgan Stanley now owns 258,317 shares of the biotechnology company’s stock valued at $1,558,000 after acquiring an additional 237,933 shares during the last quarter. Hedge funds and other institutional investors own 73.29% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.